Evidence map›Paper›PMID 41938987›Full record

ReviewClinical and translational radiation oncology2026

Prophylactic cranial irradiation in ES-SCLC: The ongoing debate from the past to the immunotherapy Era".

Tala Najdi, Antoine Richa, Mia Chamieh, Toufic Zeidan, Fares Azoury, Carine Harmouche, Hampig Raphael Kourie

Abstract readReview
In one paragraph

Review in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tala NajdiDepartment of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut, Lebanon.
Antoine RichaSaint Joseph University, Beirut, Lebanon.
Mia ChamiehSaint Joseph University, Beirut, Lebanon.
Toufic ZeidanDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Fares AzourySaint Joseph University, Beirut, Lebanon.
Carine HarmoucheSaint Joseph University, Beirut, Lebanon.
Hampig Raphael KourieDepartment of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SCLC (Small Cell Lung Cancer) is categorized into two stages: limited-stage (LS-SCLC), where the cancer is confined to a single radiation field, and extensive-stage, where the disease has spread beyond the chest, potentially including the brain. In managing extensive-stage SCLC (ES-SCLC), preventing brain metastases becomes a crucial goal, as these metastases are a major cause of mortality due to their severe complications. Prophylactic cranial irradiation (PCI) has been shown to reduce the incidence of brain metastases and, according to the pre-immunotherapy

Indexed as

Brain metastasesextensive stage small cell lung cancer (ES-SCLC)Immunotherapyprophylactic cranial irradiation (PCI)Radiotherapy

Identifiers

PMID41938987
PMCPMC13049582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.